$GLMD News
Last published 2mo ago
- 2mo agoGLMDGalmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI InnovationPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic...
- 2mo agoGLMDGalmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment TechnologyPR NewswireColospan Ltd., a wholly owned subsidiary of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), today announced the successful completion of a feasibility...
- 2mo agoGLMDGalmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer ModelsPR NewswireXtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer
- 3mo agoGLMDGalmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion MarketPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic...
- 3mo agoGLMDTentative Approval of Scomara, Nda #218528 (Type 3 - New Dosage Form)FDA Approved DrugsApproval Date: 07/20/2026; Drug Name: Scomara, Nda #218528; Active Ingredients: SIROLIMUS; Company: Aft Pharmaceuticals Ltd; Submission Status: Tentative Approval; Submission Classification: Type 3 - New Dosage Form; Application Number: 218528
- 3mo agoGLMDGalmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, AramcholPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic...
- 4mo agoGLMDGalmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of AcquisitionPR NewswireGalmed today announces that following a restructuring of the acquisition terms, it consummated the acquisition of Colospan a commercial-stage medical ...
- 5mo agoGLMDGalmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion MarketPR NewswireGalmed Pharmaceuticals Ltd. ("Galmed") (NASDAQ: GLMD) today announced that it has entered into a definitive agreement to acquire Colospan Ltd....
- 5mo agoGLMDTissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac FibrosisPR NewswireTissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused...
- 6mo agoGLMDGalmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mgPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI...
- 6mo agoGLMDTentative Approval of Finerenone, Anda #220747 (Labeling)FDA Approved DrugsApproval Date: 05/14/2026; Drug Name: Finerenone, Anda #220747; Active Ingredients: FINERENONE; Company: Macleods Pharmaceuticals Ltd; Submission Status: Tentative Approval; Submission Classification: Labeling; Application Number: 220747
- 6mo agoGLMDTissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based TherapeuticsPR NewswireTissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver ...
- 6mo agoGLMDTentative Approval of Vericiguat, Anda #220221FDA Approved DrugsApproval Date: 04/20/2026; Drug Name: Vericiguat, Anda #220221; Active Ingredients: VERICIGUAT; Company: Torrent Pharmaceuticals Ltd; Submission Status: Tentative Approval; Application Number: 220221
- 7mo agoGLMDGalmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain CancersPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI...
- 7mo agoGLMDGalmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, AramcholPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic...
- 7mo agoGLMDGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025PR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic...
- 7mo agoGLMDTentative Approval of Ruxolitinib, Anda #220375FDA Approved DrugsApproval Date: 03/23/2026; Drug Name: Ruxolitinib, Anda #220375; Active Ingredients: RUXOLITINIB; Company: Torrent Pharmaceuticals Ltd; Submission Status: Tentative Approval; Application Number: 220375
- 9mo agoGLMDGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationPR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic...
- 11mo agoGLMDAlcon Pharmaceuticals Ltd. - Appeal, AffirmedUS Patent Trial and Appeal Board
- 11mo agoGLMDGalmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 MeetingPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic...
- 11mo agoGLMDGalmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASHPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic...
- 11mo agoGLMDGalmed Issues CEO Letter to ShareholdersPR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, ...
- 11mo agoGLMDGalmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdatePR NewswireTEL AVIV, Israel, Nov. 26, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage...
- 11mo agoGLMDGalmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol MegluminePR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, ...
- 11mo agoGLMDKBLBRPTXZYMEKey Catalysts Emerge in Oncology, Synthetic Biology, and M&A Activity as Markets OpenGlobeNewswireDENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Markets open this morning with a distinctly biotech-heavy narrative delivering milestone developments. Zymeworks and Jazz Drop Landmark Phase 3 Data: Ziihera Positioned as New
- 11mo agoGLMDGalmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitroPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic...
- 1y agoGLMDTentative Approval of Vortioxetine Hydrobromide, Anda #211165FDA Approved DrugsApproval Date: 11/10/2025; Drug Name: Vortioxetine Hydrobromide, Anda #211165; Active Ingredients: VORTIOXETINE; Company: Macleods Pharmaceuticals Ltd; Submission Status: Tentative Approval; Application Number: 211165
- 1y agoGLMDActelion Pharmaceuticals Ltd. et al. vs United Therapeutics Corporation - AIA Trial, Institution DeniedUS Patent Trial and Appeal Board
- 1y agoGLMDTentative Approval of Dapagliflozin, Anda #211506FDA Approved DrugsApproval Date: 10/17/2025; Drug Name: Dapagliflozin, Anda #211506; Active Ingredients: DAPAGLIFLOZIN; Company: Macleods Pharmaceuticals Ltd; Submission Status: Tentative Approval; Application Number: 211506
- 1y agoGLMDTentative Approval of Canagliflozin And Metformin Hydrochloride, Anda #215255FDA Approved DrugsApproval Date: 10/01/2025; Drug Name: Canagliflozin And Metformin Hydrochloride, Anda #215255; Active Ingredients: METFORMIN HYDROCHLORIDE; CANAGLIFLOZIN; Company: Macleods Pharmaceuticals Ltd; Submission Status: Tentative Approval; Application Number: 215255
- 1y agoGLMDTentative Approval of Abacavir, Dolutegravir And Lamivudine, Anda #217830FDA Approved DrugsApproval Date: 09/17/2025; Drug Name: Abacavir, Dolutegravir And Lamivudine, Anda #217830; Active Ingredients: ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE; Company: Macleods Pharmaceuticals Ltd; Submission Status: Tentative Approval; Application Number: 217830
- 1y agoGLMDGalmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdatePR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and...
- 1y agoGLMDGalmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder ValuePR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver,...
- 1y agoGLMDApproval of Camcevi Etm, Nda #219745 (Type 5 - New Formulation or New Manufacturer)FDA Approved DrugsApproval Date: 08/25/2025; Drug Name: Camcevi Etm, Nda #219745; Active Ingredients: LEUPROLIDE MSEYLATE; Company: Foresee Pharmaceuticals Co Ltd; Submission Status: Approval; Submission Classification: Type 5 - New Formulation or New Manufacturer; Application Number: 219745
- 1y agoGLMDTentative Approval of Dapagliflozin And Metformin Hydrochloride, Anda #211559FDA Approved DrugsApproval Date: 08/19/2025; Drug Name: Dapagliflozin And Metformin Hydrochloride, Anda #211559; Active Ingredients: DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE; Company: Macleods Pharmaceuticals Ltd; Submission Status: Tentative Approval; Application Number: 211559
- 1y agoGLMDGalmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASHPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver,...
- 1y agoGLMDGalmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdatePR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and...
- 1y agoGLMDGalmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC ModelsPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and...
- 1y agoGLMDGalmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer ModelsPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and...
- 1y agoGLMDGalmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual FormulationPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and...
- 1y agoGLMDGalmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI CancersPR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company, today announced a sponsored...
- 1y agoGLMDGalmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 InhibitorPR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing novel...
- 1y agoGLMDGalmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 InhibitorPR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, ...
- 1y agoGLMDGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024PR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic...
- 1y agoGLMDGalmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination TherapyPR NewswireGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic...
- 2y agoGLMDGalmed publishes Results from Aramchol Phase 3 Open Label part in HepatologyPR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...
- 2y agoGLMDMRKNVSONCY+1How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for BiotechsGlobeNewswirePALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in
- 2y agoGLMDGalmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic DiseasesPR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for fibroinflammatory indications...
- 2y agoGLMDGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023PR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic...
- 2y agoGLMDGalmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisPR NewswireGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic...